Primary mediastinal large B cell lymphoma (PMBCL) is a recognized nonHodgkin lymphoma entity with unique pathological, clinical and molecular characteristics distinct from those of other diffuse large B cell lymphomas.
Introduction
Primary mediastinal large B cell lymphoma (PMBCL) represents approximately 2-4% of all non-Hodgkin lymphomas. 1 Distinguishing PMBCL from other forms of DLBCL can be viewed as a paradigm for reclassification of cancer subtypes based on molecular features, as the molecular characterization of PMBCL highlighted an overlap with the nodular sclerosis (NS) subtype of classical Hodgkin lymphoma (cHL) sharing a number of genetic and gene expression features 3, 4 . Interestingly, this association had been long suspected based on similarities in clinical features and reports of sequential or composite occurrences of cHL and PMBCL 5, 6 . Functional analyses of both lymphomas confirmed that the malignant cells rely on the same principal signaling pathways, namely JAK-STAT and NFκB signaling, both providing these cells with a proliferative advantage. [7] [8] [9] However, more recent lines of evidence also suggest that acquired immune privilege by the malignant cells contributes to
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From the cancer phenotype of PMBCL in a cooperative way. 10, 11 The specific composition of the inflammatory infiltrates discovered through histological study of primary PMBCL biopsies further supports the significance of the interactions of the malignant cells with the surrounding non-neoplastic immune cells. Unraveling the underlying genetic mechanism(s) of these tumor-microenvironment interactions might be important for future therapies targeting the immune privilege phenotype of the malignant cells.
From a clinical point of view, PMBCL patients treated with multi-agent chemotherapy appear to have a better survival compared to DLBCL based on retrospective analyses. 12,13 However, the intensity of primary chemotherapy, the role of radiotherapy and the effectiveness of added rituximab are still the subject of debate and definitive conclusions are hampered by the paucity of prospective studies. Equally, meaningful biomarker studies to inform risk stratification and outcome prediction of PMBCL are largely unavailable.
With a number of important biological insights in PMBCL reported in the last 12 months, a critical review of the molecular pathogenesis of this disease was warranted. We will first focus on the pathological and clinical features of PMBCL to define in detail the disease entity in comparison to related lymphoid cancers. We will then characterize the genetic alterations and deregulated signaling pathways that underlie the pathogenesis and review the recent data that highlight the importance of the microenvironment. Finally, we will pay special attention to the potential synergy of the underlying genetic alterations that
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Pathology and Clinical features
PMBCL characteristically presents with a bulky anterior mediastinal mass and affects predominantly female patients in their third or fourth decade of life (Figure 1) .
14 PMBCL can also occur in children and adolescents showing similar clinical and pathological characteristics with adult cases. 15 In contrast to DLBCL 16 , the bone marrow is rarely involved and the tumor extension is typically 19, 20 . Consolidating radiation therapy has also been studied in non-comparator studies. 21 However, it remains to be determined if the addition of rituximab immunotherapy is making radiation and high-dose therapies obsolete. Very recent reports of combining rituximab with dose-adjusted EPOCH have shown very promising results
20
, and equally, PMBCL subgroup analysis of a randomized DLBCL trial (Mabthera International
Trial group study/MINT) showed increased response rates and event-free survival in patients receiving rituximab that was similar to the benefit seen in DLBCL patients.
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Of note, most of the prognostic factors that were established in DLBCL 1, 23 . Although histopathologic and genetic data are limited, recent molecular studies confirm the transitional nature of mediastinal GZL existing in the borderland between PMBCL and cHL [24] [25] [26] . Figure 1 highlights the most prominent clinical, morphological and molecular features recognized in PMBCL, cHL, DLBCL and mediastinal GZL demonstrating the biological continuum of these B cell lymphomas. However, the main focus of this review is PMBCL and reference to the related entities will only be made if relevant to the molecular pathogenesis of PMBCL.
Based on immunophenotypic data and mutational analysis of various loci that are typical targets of somatic hypermutation (SHM), PMBCL has been suggested to be of germinal center or post-germinal center origin. 27 
NFκB signaling pathway
The nuclear factor kappa B (NFκB) signaling pathway has been described as one of the most important dysregulated pathways in the malignant pathogenesis of B cell lymphomas, and of cHL and PMBCL in particular (for detailed review of HL see ref. Genomic amplification of a subtelomeric region of chromosome 9 (9p24.1)
involving several genes including JAK2 has been consistently reported in more than half of cases and can be considered as one of the hallmark genetic alterations in PMBCL. 10,46,60,61 ( . Furthermore, MHC class II loss was found to be correlated with a decreased numbers of infiltrating cytotoxic T cells in PMBCL, 77 and a similar correlation was previously described in DLBCL suggesting a possible mechanism of escape from immune surveillance. 78 Specifically, of 92 PMBCL cases, 65% were negative for HLA-DR protein . These data suggest a distinct mechanism compared to immune-privileged site-associated B cell lymphomas 80, 81 , such as testicular or primary central nervous system (CNS)
The tumor microenvironment of PMBCL
lymphomas, in which copy number loss as a result of deletion at the HLA locus
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From on chromosome 6p21.3 has been recurrently described in over 60% of cases.
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By contrast, in PMBCL, chromosomal loss of a distinct region on 6p21 harboring the MHC class I and II genes has only been seen in a small number of cases. in PMBCL (38%) and cHL (15%), but only rarely found in DLBCL (3%). In PMBCL these breaks were also linked to inferior disease-specific survival.
Moreover, CIITA was found as a promiscuous gene with various partners resulting in novel in-frame gene fusions and strikingly, in these cases with gene fusions, a cluster breakpoint region of 1.6kb in CIITA intron 1 could be identified, disrupting normal CIITA transcription of this allele. Interestingly, in some cases CIITA breaks were shown to occur in more than one allele raising the possibility that CIITA rearrangements might lead to complete loss of function. Of note, CIITA coding sequence mutations have been described in a small number of DLBCL 83 , but the functional consequences remain unclear. The CIITA gene was initially found in studies of patients with bare lymphocyte syndrome (BLS, complementation group A), a rare autosomal recessive disease characterized by mutations in CIITA leading to loss of MHC class II expression and clinical manifestations due to an immunodeficiency phenotype. 84 Several groups found that CIITA functions as a transactivator in a complex of transcription factors (RFX, NFY, X2BP) that bind to class II MHC promoters. 85 Previous studies also . These data suggest that, in addition to haploinsufficiency of CIITA, MHC class II expression may be suppressed in a dominant-negative manner (Figure 3) . In summary, CIITA breaks likely lead to loss of MHC class II expression and might explain, in part, the previously identified clinical correlations discussed above.
Overexpression of PD-1 ligands (PDL1/CD274, PDL2/PDCD1LG2)
The surface molecule PDCD1LG2 (CD273, PDL2) has been identified as a highly overexpressed PMBCL-specific gene by GEP. It is harbored in the common amplicon on chromosome 9p (see above) 3 
Synergy of alterations and perspective
Similar to other cancers, the pathogenesis of PMBCL is presumably a multi-step process with accumulation of multiple genetic alterations. In the following section we will discuss the simultaneous consequences of unbalanced chromosome 16p13.13 rearrangements and chromosomal gain of the 9p24 amplicon ( Table 2) . Finally we will outline how the dependence of PMBCL on some of the previously described key pathways might be translated into novel therapeutic approaches. 
Chromosomal gain of 9p24
As discussed above, amplification of a well-defined region on chromosome 9p24 has been identified in the majority of cases and can be considered as one of the genetic hallmark events of PMBCL pathogenesis.
However, only recently have systematic approaches identified the target genes in the amplicon that are overexpressed and prove to be functionally most relevant.
Remarkably, these studies did not identify a single target gene, but revealed that multiple genes are co-amplified and cooperate in the pathogenesis. 
